Gilead paid $80 million upfront for global rights to Genhouse Bio's clinic-ready synthetic‑lethal cancer drug from China, expanding its oncology portfolio.
Longevity News
Gilead Sciences has secured another synthetic lethal therapy, handing $80 million upfront for the global rights to a...
Source: FierceBiotech - Biotech • Published: 19 Feb 2026, 22:00
Continue exploring
Related longevity signals
Frontiers - HealthAcute otitis media complicated by mastoiditis and otogenic transverse-sigmoid sinus thrombosis in an adult: a case report on infectious pathogenesis and multidisciplinary therapyA clinical case describing adult acute otitis media that progressed to mastoiditis with sigmoid plate erosion and transverse-sigmoid sinus thrombosis, and multidisciplinary management.PR NewswireHenlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNCReport on a biopharma's midyear financial and commercial update highlighting global sales momentum and pipeline progress in oncology.Longevity TechnologyXellSmart scores FDA fast track for Parkinson’s cell therapyNews about regulatory momentum for an off-the-shelf cell therapy for Parkinson’s, previewing a piece on its clinical and manufacturing implications.PR NewswirePixelgen Technologies Closes $15.5M Oversubscribed Series B to Accelerate Global ExpansionPixelgen's funding and board moves are the focus, previewing an article about a life‑science startup accelerating commercialization and global growth.